INTI Company Profile and Key Details

Average 10-day trading volume of 800.00 shares is below the 3-month average of 17.01 thousand, indicating normal recent market interest.

Inhibitor Therapeutics, Inc. (OTC:INTI) closed at $0.10 USD, gaining $0.01 (14.94%) from the previous close of $0.09. The stock is currently mid-range between its 52-week high and low $0.04 and $0.12. With a market capitalization of about $17.26 million, Inhibitor Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.70). Key stats such as the average daily volume over the past year has been around 7.42 thousand shares, volume is running light vs its 52-week average. Headquartered in Tampa, FL, Inhibitor Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Francis E. O'Donnell Jr., the company employs approximately 8 people and listed since September 13, 2013. Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise.

Inhibitor Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.01. This means the shares are trading above this model’s fair value.

Inhibitor Therapeutics, Inc. has 172.57 million shares outstanding. The public float is 77.56 million shares, elevated short interest at 0.36% of float. This equals 19.88 thousand shares. The short ratio is 0.08 days. Institutional investors hold 0.0% of the float. Insiders own 57.16%. HedgePath, LLC holds 79.63 million shares, ODONNELL FRANCIS E JR has 11.44 million shares and Hasara Garrison J. has 3.97 million shares.

Valuation shows Inhibitor Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.11.

Our AI price prediction model suggests that Inhibitor Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Inhibitor Therapeutics, Inc. trades at a P/E ratio of -3.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -4.02 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.18, also below market averages.